NCT04738357已完成3 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia
Haisco Pharmaceutical Group Co., Ltd.1 个研究点 分布在 1 个国家目标入组 276 人开始时间: 2021年3月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 276
- 试验地点
- 1
- 主要终点
- Sum of Pain Intensity Differences (SPID)
研究概览
简要总结
This study is a multi-center, randomized, double-blind, placebo-controlled study. A total of 276 subjects undergoing elective laparoscopic surgery under general anesthesia are planned to be enrolled and randomized into 2 groups, i.e., the HSK21542 group (138 subjects) and the placebo group (138 subjects).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 ≤ age ≤ 70 years old, with no gender requirement;
- •American Society of Anesthesiologists (ASA) Class I-II;
- •BMI ≥ 18 kg/m2 and ≤ 40 kg/m2;
- •Subjects undergoing elective laparoscopic surgery under general anesthesia with an expected surgery duration of 1-5 h (inclusive);
- •Agree to participate in this trial and voluntarily sign the informed consent form;
排除标准
- •With a history of allergy to opioids, such as urticaria, or allergic to intraoperative anesthetics as prescribed in the protocol;
- •Patients with history or evidence of any of the following diseases prior to screening:
- •History of cardiovascular diseases: uncontrolled hypertension (systolic blood pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 mmHg without treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment), aneurysm, severe arrhythmia, heart failure, Adams-stokes syndrome, New York Heart Association (NYHA) Class ≥ III, severe superior vena cava syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medical treatment, II-III degree atrioventricular block (excluding patients with pacemakers);
- •History of respiratory system disorders: severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, throat mass, history of tracheoesophageal fistula or airway tear, severe respiratory infection within 2 weeks prior to screening;
- •History of neurological and psychiatric disorders: craniocerebral injury, convulsions, intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents; schizophrenia, mania, insanity, long-term use of psychotropic drugs, and history of cognitive dysfunction; history of depression, anxiety, and epilepsy, etc.;
- •Have undergone any major surgery within 3 months prior to screening, which may affect postoperative pain assessment as judged by the investigator;
- •In receipt of any one of the following medications or treatments at screening:
- •A time between the last use of opioid and non-opioid (such as paracetamol, aspirin [daily dose > 100 mg], indometacin, diclofenac, parecoxib sodium, and other non-steroidal anti-inflammatory drugs) analgesics and randomization of shorter than 5 half-lives of the drug or the duration of response (whichever is longer);
- •Longer than 10 days of continuous use of opioid analgesics for any reason within 3 months prior to screening;
- •Use of drugs with unknown half-life that affect the analgesic effect within 14 days before randomization, or the last use of drugs that affect the analgesic effect is within 5 half-lives (as per the packaging insert of the drug) apart from randomization, such drugs include but are not limited to: sedative-hypnotics (benzodiazepines [triazolam, diazepam, midazolam, etc.], non-benzodiazepines [zolpidem, zopiclone, zaleplon, etc.]), sedative anesthetics (sevoflurane, anesthetic ether, nitrous oxide, thiopental sodium, ketamine, etomidate, etc.), glucocorticoids (dexamethasone hydrochloride, methylprednisolone, etc.), antiepileptics (carbamazepine, sodium valproate, etc.), anxiolytics (chlordiazepoxide, diazepam, etc.), antidepressants (imipramine, amitriptyline, etc.), and Chinese herbal medicines or Chinese patent medicines with analgesic and sedative effects;
- •Expected to receive any anti-tumor drug or therapy from 14 days prior to randomization to the end of the follow-up period, including but not limited to chemotherapy drugs, targeted drugs, and Chinese herbal medicines;
- •A time between randomization and the last use of diuretics and compound drugs containing diuretics of shorter than 5 half-lives of the drug or the duration of response (whichever is longer);
- •The laboratory parameters measured at screening period reach one of the following criteria:
- •WBC < 3.0 × 109/L;
- •Platelet count < 80 × 109/L;
- •Hemoglobin < 70 g/L;
- •Prothrombin time > 1.5 × ULN;
- •Activated partial thromboplastin time > 1.5 × ULN;
- •Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2 × ULN;
- •Total bilirubin > 1.5 × ULN;
- •Blood creatinine > 1.5 × ULN;
- •Fasting blood glucose ≥ 11.1 mmol/L;
- •Positive for hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody at screening;
- •History of medication or drug abuse and/or alcohol abuse within 3 months prior to screening (alcohol abuse is defined as an average of > 2 units of alcohol consumed per day [1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol, or 150 mL of wine]);
- •History of blood donation or blood loss of ≥ 400 mL within 3 months prior to screening;
- •Have participated in other clinical trials within 3 months prior to screening (defined as having received investigational product or placebo);
- •Pregnant or breastfeeding females; women of child-bearing potential or men who are unwilling to use contraception during the trial; or subjects who are planning pregnancy within 3 months after the completion of the trial (including male subjects);
- •Subject judged by the investigator to have any other factors unsuitable for involvement in the study.
研究组 & 干预措施
HSK21542
Experimental
干预措施: HSK21542 (Drug)
placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Sum of Pain Intensity Differences (SPID)
时间窗: Frome administration until 24 hours after administration
The time-weighted SPID at rest within 0-24 h after the first postoperative administration in each group
次要结局
- The proportion of subjects with a NRS of ≤ 3(Frome administration until 24 hours after administration)
- The incidence and severity of AEs(from signing the informed consent form to the follow-up period (D8 ± 1 postoperative).)
- Sum of Pain Intensity Differences (SPID)(Frome administration until 12 hours after administration)
- Use of remedial analgesics(Frome administration until 24 hours after administration)
- Pain Intensity Differences（PID）(Frome administration until 24 hours after administration)
- Duration of analgesia(Frome administration until 24 hours after administration)
- Satisfaction scores on postoperative analgesia(Frome administration until 24 hours after administration)
- Cumulative used amount and ratio of antiemetics(Frome administration until 24 hours after administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain TreatmentPostoperative AnalgesiaNCT05390905Haisco Pharmaceutical Group Co., Ltd.387
Unknown
3 期
Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant ChemotherapyHigh-grade OsteosarcomaNCT04359550Lee's Pharmaceutical Limited362
已完成
2 期
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye DropsCorneal Epithelium DefectNCT06209203Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.120
已完成
3 期
A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis SymptomsOsteoarthritis of KneeOsteoarthritis, KneeNCT06693648Amzell549
已完成
3 期
A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated PruritusHemodialysis Patients with Moderate-to-Severe PruritusPruritusNCT05135390Haisco Pharmaceutical Group Co., Ltd.545